Oncolytic herpes virus with defective ICP6 specifically replicates in quiescent cells with homozygous genetic mutations in p16 (original) (raw)

• Aghi M, Martuza RL . (2005). Oncolytic viral therapies—the clinical experience. Oncogene 24: 7802–7816.
  Article CAS Google Scholar
• Burns KL, Ueki K, Jhung SL, Koh J, Louis DN . (1998). Molecular genetic correlates of p16, cdk4, and pRb immunohistochemistry in glioblastomas. J Neuropathol Exp Neurol 57: 122–130.
  Article CAS Google Scholar
• Costello JF, Berger MS, Huang HS, Cavenee WK . (1996). Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation. Cancer Res 56: 2405–2410.
  CAS PubMed Google Scholar
• Elledge SJ, Zhou Z, Allen JB . (1992). Ribonucleotide reductase: regulation, regulation, regulation. Trends Biochem Sci 17: 119–123.
  Article CAS Google Scholar
• Farassati F, Yang AD, Lee PW . (2001). Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nat Cell Biol 3: 745–750.
  Article CAS Google Scholar
• Finney DJ. . (1971). Probit Analysis. Cambridge University Press: New York, NY.
  Google Scholar
• Fu X, Tao L, Cai R, Prigge J, Zhang X . (2006). A mutant type 2 herpes simplex virus deleted for the protein kinase domain of the ICP10 gene is a potent oncolytic virus. Mol Ther 13: 882–890.
  Article CAS Google Scholar
• Goldstein DJ, Weller SK . (1988). Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant. Virology 166: 41–51.
  Article CAS Google Scholar
• Gray-Bablin J, Rao S, Keyomarsi K . (1997). Lovastatin induction of cyclin-dependent kinase inhibitors in human breast cells occurs in a cell cycle-independent fashion. Cancer Res 57: 604–609.
  CAS PubMed Google Scholar
• Hoshino T, Prados M, Wilson CB, Cho KG, Lee KS, Davis RL . (1989). Prognostic implications of the bromodeoxyuridine labeling index of human gliomas. J Neurosurg 71: 335–341.
  Article CAS Google Scholar
• Ikeda K, Ichikawa T, Wakimoto H, Silver JS, Deisboeck TS, Finkelstein D et al. (1999). Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med 5: 881–887.
  Article CAS Google Scholar
• Jiang H, Gomez-Manzano C, Alemany R, Medrano D, Alonso M, Bekele BN et al. (2005). Comparative effect of oncolytic adenoviruses with E1A-55 kDa or E1B-55 kDa deletions in malignant gliomas. Neoplasia 7: 48–56.
  Article CAS Google Scholar
• Kamiryo T, Tada K, Shiraishi S, Shinojima N, Nakamura H, Kochi M et al. (2002). Analysis of homozygous deletion of the p16 gene and correlation with survival in patients with glioblastoma multiforme. J Neurosurg 96: 815–822.
  Article CAS Google Scholar
• Kirn D, Martuza RL, Zwiebel J . (2001). Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat Med 7: 781–787.
  Article CAS Google Scholar
• Komata T, Kondo Y, Koga S, Ko SC, Chung LW, Kondo S . (2000). Combination therapy of malignant glioma cells with 2-5A-antisense telomerase RNA and recombinant adenovirus p53. Gene Therapy 7: 2071–2079.
  Article CAS Google Scholar
• McCart JA, Ward JM, Lee J, Hu Y, Alexander HR, Libutti SK et al. (2001). Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res 61: 8751–8757.
  CAS PubMed Google Scholar
• Nakamura M, Konishi N, Hiasa Y, Tsunoda S, Nakase H, Tsuzuki T et al. (1998). Frequent alterations of cell-cycle regulators in astrocytic tumors as detected by molecular genetic and immunohistochemical analyses. Brain Tumor Pathol 15: 83–88.
  Article CAS Google Scholar
• Nakamura T, Peng KW, Harvey M, Greiner S, Lorimer IA, James CD et al. (2005). Rescue and propagation of fully retargeted oncolytic measles viruses. Nat Biotechnol 23: 209–214.
  Article CAS Google Scholar
• Norman KL, Hirasawa K, Yang AD, Shields MA, Lee PW . (2004). Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection. Proc Natl Acad Sci USA 101: 11099–11104.
  Article CAS Google Scholar
• Ohgaki H, Kleihues P . (2007). Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170: 1445–1453.
  Article CAS Google Scholar
• Ono Y, Tamiya T, Ichikawa T, Kunishio K, Matsumoto K, Furuta T et al. (1996). Malignant astrocytomas with homozygous CDKN2/p16 gene deletions have higher Ki-67 proliferation indices. J Neuropathol Exp Neurol 55: 1026–1031.
  Article CAS Google Scholar
• O'Shea CC, Soria C, Bagus B, McCormick F . (2005). Heat shock phenocopies E1B-55 K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy. Cancer Cell 8: 61–74.
  Article CAS Google Scholar
• Sharpless NE, Bardeesy N, Lee KH, Carrasco D, Castrillon DH, Aguirre AJ et al. (2001). Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature 413: 86–91.
  Article CAS Google Scholar
• Smith KD, Mezhir JJ, Bickenbach K, Veerapong J, Charron J, Posner MC et al. (2006). Activated MEK suppresses activation of PKR and enables efficient replication and in vivo oncolysis by Deltagamma(1)34.5 mutants of herpes simplex virus 1. J Virol 80: 1110–1120.
  Article CAS Google Scholar
• Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N et al. (2000). Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 6: 821–825.
  Article CAS Google Scholar
• Ueki K, Ono Y, Henson JW, Efird JT, Von Deimling A, Louis DN . (1996). CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 56: 150–153.
  CAS PubMed Google Scholar
• Wang CC, Liao YP, Mischel PS, Iwamoto KS, Cacalano NA, McBride WH . (2006). HDJ-2 as a target for radiosensitization of glioblastoma multiforme cells by the farnesyltransferase inhibitor R115777 and the role of the p53/p21 pathway. Cancer Res 66: 6756–6762.
  Article CAS Google Scholar
• Watanabe T, Nakamura M, Yonekawa Y, Kleihues P, Ohgaki H . (2001). Promoter hypermethylation and homozygous deletion of the p14ARF and p16INK4a genes in oligodendrogliomas. Acta Neuropathol (Berl) 101: 185–189.
  CAS Google Scholar
• Wein LM, Wu JT, Kirn DH . (2003). Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery. Cancer Res 63: 1317–1324.
  CAS PubMed Google Scholar
• Wurdinger T, Verheije MH, Raaben M, Bosch BJ, De Haan CA, Van Beusechem VW et al. (2005). Targeting non-human coronaviruses to human cancer cells using a bispecific single-chain antibody. Gene Therapy 12: 1394–1404.
  Article CAS Google Scholar
• Yoon SS, Carroll NM, Chiocca EA, Tanabe KK . (1999). Influence of p53 on herpes simplex virus type 1 vectors for cancer gene therapy. J Gastrointest Surg 3: 34–48.
  Article CAS Google Scholar